Jaguar Health, Inc. (JAGX) |
|
4.7 0.19 (4.21%)
|
01-27 16:00 |
|
Open: |
4.47 |
Pre. Close: |
4.51 |
|
High:
|
4.77 |
Low:
|
4.45 |
|
Volume:
|
311,528 |
Market Cap:
|
9(M) |
|
|
|
Technical analysis |
as of: 2023-01-27 4:45:41 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 7.18 One year: 8.38 |
| Support: |
Support1: 2.39 Support2: 0.08 |
| Resistance: |
Resistance1: 6.15 Resistance2: 7.18 |
| Pivot: |
1.69 |
| Moving Average: |
MA(5): 4.9 MA(20): 1.29
MA(100): 0.37 MA(250): 0.39 |
| MACD: |
MACD(12,26): 1.1 Signal(9): 0.6 |
| Stochastic oscillator: |
%K(14,3): 76.4  %D(3): 79 |
| RSI: |
RSI(14): 83.4 |
| 52-week: |
High: 6.15 Low: 0.08 |
| Average Vol(K): |
3-Month: 7,928 (K) 10-Days: 10,590 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ JAGX ] has closed below upper band by 17.1%. Bollinger Bands are 2061.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
4.77 - 4.8 |
4.8 - 4.82 |
|
Low:
|
4.4 - 4.42 |
4.42 - 4.44 |
|
Close:
|
4.66 - 4.7 |
4.7 - 4.74 |
|
Company Description |
|
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer for multiple possible follow-on indications, including cancer therapy-related diarrhea; orphan-drug indications for symptomatic relief of diarrhea in infants and children with congenital diarrheal disorders and for adult and pediatric patients for short bowel syndrome with intestinal failure with; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops lechlemer, a second-generation anti-secretory agent for cholera; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. Jaguar Health, Inc. was founded in 2013 and is headquartered in San Francisco, California. |
Headline News |
Thu, 26 Jan 2023
Jaguar Health to submit application to begin trial for ultra-rare ... - Seeking Alpha
Tue, 24 Jan 2023
Here's Why Jaguar Health (JAGX) Stock Is Volatile Tuesday - Benzinga
Mon, 23 Jan 2023
Why Is Intelligent Bio Solutions (INBS) Stock Up 363% Today? - InvestorPlace
Mon, 23 Jan 2023
Is Jaguar Health (JAGX) Stock Really Up 6800%? - InvestorPlace
Mon, 23 Jan 2023
Jaguar Health (NASDAQ:JAGX) Is Carrying A Fair Bit Of Debt - Simply Wall St
Fri, 20 Jan 2023
Thinking about buying stock in Salarius Pharmaceuticals ... - PR Newswire
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
151 (M) |
| Shares Float |
130 (M) |
|
% Held by Insiders
|
19.4 (%) |
|
% Held by Institutions
|
3.9 (%) |
|
Shares Short
|
8,470 (K) |
|
Shares Short P.Month
|
6,630 (K) |
Stock Financials |
|
EPS
|
-1.3 |
|
EPS Est Next Qtl
|
-0.08 |
|
EPS Est This Year
|
-0.69 |
|
EPS Est Next Year
|
-0.22 |
|
Book Value (p.s.)
|
0.02 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-361.5 |
|
Return on Assets (ttm)
|
-44.1 |
|
Return on Equity (ttm)
|
-433.3 |
|
Qtrly Rev. Growth
|
400 |
|
Gross Profit (p.s.)
|
0.01 |
|
Sales Per Share
|
0.07 |
|
EBITDA (p.s.)
|
-0.25 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-36 (M) |
|
Levered Free Cash Flow
|
-14 (M) |
Stock Valuations |
|
PE Ratio
|
-3.63 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
156.66 |
|
Price to Sales
|
65.93 |
|
Price to Cash Flow
|
-19.97 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2019-06-06 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
